Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03930875 · ClinicalTrials.gov registry record

Aspirin Resistance in OSA Patients

A clinical trial of Obstructive Sleep Apnea, sponsored by Danbury Hospital.

Completed
Registry status
63
Enrollment target
1
Study location

NCT03930875 is a study of Obstructive Sleep Apnea that has completed, run by Danbury Hospital. The registered enrollment target is 63 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03930875, a study of Obstructive Sleep Apnea, has completed, sponsored by Danbury Hospital.

COMPLETED
Registry status
63 participants
Enrollment target
1
Study location

Study Summary

Obstructive Sleep Apnea (OSA) patients are at increased risk of major cardiovascular events, so many patients take aspirin for prevention. Poor responsiveness to aspirin is a major clinical concern because it can potentially worsen the prognosis of OSA patients. However, continuous positive airway pressure (CPAP) therapy that is considered standard of care for OSA treatment may potentially lead to improvement in responsiveness to aspirin. This study will determine whether CPAP therapy decreases patients' aspirin resistance in OSA patients with a new diagnosis or existing moderate to severe OSA who are treated with CPAP and take aspirin for prevention.

Conditions Studied

Interventions

  • OTHER Aspirin Resistance testing

Study Locations (1)

Connecticut

  • Danbury Hospital - Danbury

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2017-12-12
Est. Completion 2018-09-07

Sponsor

Danbury Hospital

7 total trials

What the Registry Record Tells You About NCT03930875

The ClinicalTrials.gov registry entry for NCT03930875 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (71% lower). The listed sponsor is Danbury Hospital, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which Aspirin Resistance testing is the first listed.

NCT03930875 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03930875 about?

NCT03930875 is a clinical study titled "Aspirin Resistance in OSA Patients". Obstructive Sleep Apnea (OSA) patients are at increased risk of major cardiovascular events, so many patients take aspirin for prevention. Poor responsiveness to aspirin is a major clinical concern because it can potentially worsen the prognosis of OSA patients. However, continuous positive airway p...

What is the current status of trial NCT03930875?

This trial is currently completed. The enrollment target is 63 participants. The study started on 2017-12-12. Estimated completion is 2018-09-07.

What conditions does trial NCT03930875 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea.

What interventions are being tested in trial NCT03930875?

The interventions under investigation include: Aspirin Resistance testing (OTHER).

Who is sponsoring clinical trial NCT03930875?

This trial is sponsored by Danbury Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03930875 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.